Why Whitehawk Therapeutics, Inc.’s (WHWK) Stock Is Down 7.84%

By Rosalio Madrigal
November 21, 2026
Featured Tickers:

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Whitehawk Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Whitehawk Therapeutics, Inc.’s stock price such as:

  • Whitehawk Therapeutics, Inc.’s current stock price and volume
  • Why Whitehawk Therapeutics, Inc.’s stock price changed recently
  • Upgrades and downgrades for WHWK from analysts
  • WHWK’s stock price momentum as measured by its relative strength

About Whitehawk Therapeutics, Inc. (WHWK)

Before we jump into Whitehawk Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Want to learn more about Whitehawk Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Whitehawk Therapeutics, Inc..

Learn More About A+ Investor

Whitehawk Therapeutics, Inc.’s Stock Price as of Market Close

As of November 20, 2026, 4:00 PM, CST, Whitehawk Therapeutics, Inc.’s stock price was $3.070.

Whitehawk Therapeutics, Inc. is down 1.6% from its previous closing price of $3.120.

During the last market session, Whitehawk Therapeutics, Inc.’s stock traded between $2.957 and $3.140. Currently, there are approximately 93.87 million shares outstanding for Whitehawk Therapeutics, Inc..

Whitehawk Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Whitehawk Therapeutics, Inc. Stock Price History

Whitehawk Therapeutics, Inc.’s (WHWK) price is currently down 5.25% so far this month.

During the month of November, Whitehawk Therapeutics, Inc.’s stock price has reached a high of $3.380 and a low of $2.910.

Over the last year, Whitehawk Therapeutics, Inc. has hit prices as high as $5.495 and as low as $1.975. Year to date, Whitehawk Therapeutics, Inc.’s stock is up 26.86%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Whitehawk Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 20, 2026, there was 1 analyst who downgraded Whitehawk Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Whitehawk Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Whitehawk Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Whitehawk Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Whitehawk Therapeutics, Inc. (WHWK) by visiting AAII Stock Evaluator.

Relative Price Strength of Whitehawk Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 20, 2026, Whitehawk Therapeutics, Inc. has a weighted four-quarter relative price strength of 5.47%, which translates to a Momentum Score of 71 and is considered to be Strong.

Want to learn more about how Whitehawk Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Whitehawk Therapeutics, Inc. Stock Price: Bottom Line

As of November 20, 2026, Whitehawk Therapeutics, Inc.’s stock price is $3.070, which is down 1.6% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Whitehawk Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Learn More About A+ Investor

Find New Stock Opportunities With Included With AAII Platinum
Est Rev: Up 5% Screen: 21.7% Compared to S&P 500
at only 6.9%

Since Inception. Data as of 12/31/2024.




Try AAII Platinum and get full access to
769.3% Stock Superstars Portfolio Total Return Since Inception
Compare to:
710.3% iShare DOW Jones
U.S. Index ETF (IYY)

SSR Group 3 O'Shaughnessy portfolio has a 411.2% gain since inception performance compared to IYY at only 119.1%% Performance as of 11/29/24.

Get your free copy of our special report analyzing the tech stocks most likely to outperform the market.

Download the FREE Report Here:

BECOME A MEMBER FOR ONLY $2

Get access to powerful investment discovery tools and a wealth of investment education to help you achieve your financial goals.